Allorion Therapeutics named ARTS-011 as the development candidate for its TYK2 program. The preclinical data for ARTS-011 will be presented on May 7 in a poster session at the American Association of Immunologists (AAI) Annual Meeting 2022 in Portland, Oregon.
Read MoreAllorion Therapeutics named ARTS-021 as the development candidate for its CDK2 program. The preclinical data for ARTS-021 will be presented on April 12 in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, Louisiana.
Read MorePrecision-med biotech Allorion Therapeutics is expanding — and now has tens of millions of dollars more to work with.
In the MediaAllorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, today announced the completion of $40M Series A financing.
Read MoreAllorion Therapeutics established laboratories at our Natick and Guangzhou sites and put them into operation, enabling us to carry out biological and chemical experiments in-house. Together with our contract research organizations, these internal experimental facilities will further strengthen our R&D capabilities.